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Background: Regenerating gene (REG) family is composed of antiapoptotic factors and growth factors that affect
epithelial cells within the digestive system. Regenerating gene-I has been studied in different cancers. However, it
has never been studied in head and neck cancer. We investigated the expression of REG-I in head and neck SCC
and its relevance to patient survival rates.
Methods: Untreated biopsy specimens of 60 patients with stage IV head and neck SCC were collected, and the
expression of REG-I was evaluated using immunohistochemistry. The association between REG-I expression and
clinico-pathological features or survival status of the patients was assessed by Chi-square test, Fisher’s exact test and
Kaplan-Meier method. Cox proportional hazard model was used to identify the independent prognostic factors.
Results: Incidence of lymphatic permeation, vascular invasion and pathological lymph nodes was significantly
higher in REG-I negative group (p = 0.008, 0.030 and 0.015, respectively). Overall and cancer-free survival rates were
significantly higher in REG-I positive group (p = 0.000434 and 1.0847E-8, respectively). Univariate analysis showed
that REG-I was an independent prognostic factor for predicting long-term overall survival (p = 0.002), and multivariate
analysis showed that REG-I and lymphatic permeation were independent prognostic factors for predicting long-term
disease-free survival (p = 0.001 and 0.022, respectively).
Conclusion: Our results showed for the first time that, REG-I is expressed in head and neck SCC. REG-I expression is
associated with a longer survival status. We conclude that, REG-I might be a prognostic marker in head and neck SSC
and should be further investigated.
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Head and neck cancers include malignant neoplasms
that arise from many sites within the upper aerodigestive
tract, with the most common sites being the oropharynx,
hypopharynx, larynx, and oral cavity [1]. Most of these
epithelial malignancies are squamous cell carcinoma of
the head and neck (SCCHN), for which the most im-
portant risk factors are tobacco and alcohol consump-
tion [2]. However, there is increasing evidence that the* Correspondence: ishioto@med.akita-u.ac.jp
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thirds of patients with SCCHN present with advanced
stage disease, mainly involving the regional lymph nodes;
and 10 % of patients have distant metastasis at initial
presentation [4]. Detection of factors that affect the
prognosis of these advanced cancers is important to ob-
tain an even better outcome. Regenerating gene (REG)
was firstly isolated as up-regulated gene in regenerating
islet cells [5]. Regenerating gene family members that
have been reported in humans include REG Iα, REG Iβ,
REG III, HIP/PAP and REG IV [6], with an association
between REG-I expression and islet cell replication [7].
It has recently been shown that REG-I expression pre-
dicts long-term survival in locally advanced thoracicle is distributed under the terms of the Creative Commons Attribution 4.0
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there have been no reports regarding the expression of
REG-I in head and neck squamous cell carcinoma. In
this study, we investigated REG-I expression and its
correlation with the clinico-pathological features and
survival status in stage IV head and neck squamous
cell carcinoma.
Methods
Patients and tissue samples
The medical records of 60 patients who were treated for
stage IV head and neck squamous cell carcinoma at
Akita university hospital were investigated. Of these pa-
tients, 22 (36.7 %) were diagnosed as T1 or T2, and the
other 38 (63.3 %) were diagnosed as T3 or T4. The age
of the patients ranged from 28 to 85 years, with a mean
age of 63.7 ± 11SD. All patients had received preopera-
tive radiotherapy of 40 Gray and chemotherapy (taxotel
or docetaxel 10 mg/m2/week) followed by surgery. The
clinico-pathological characteristics of the patients are
shown in Table 1.
The expression of REG-I in biopsy specimens, ob-
tained from all patients prior to therapy, was examined
to avoid the effect of radio-chemotherapy on the results.
Immunohistochemistry
We prepared deparaffinized sections of untreated biopsy
specimens of head and neck cancer for immunohisto-
chemical staining for REG-I; they were initially auto-
claved for 15 min at 121 °C, then were blocked with
0.3 % hydrogen peroxide in methanol for 30 min at
room temperature and with 10 % BSA/TBS for 30 min
at room temperature. All sections were kept overnight atTable 1 Patients’ characteristics
Variables Number of cases
(N = 60)




Lymphatic permeation (Yes/No) 32/28
Vascular invasion (Yes/No) 22/38
Pathological lymph nodes (Yes/No) 25/35
REG-I expression (Positive/Negative) 36/24
Grades (I, П, Ш) 19/22/19
Site (Oropharynx, Hypopharynx, Tongue, Larynx) 13/19/15,13
Events
Death (overall survival)
Death or recurrence (disease free survival)
14
404 °C in phosphate-buffered saline containing anti-REG-I
monoclonal antibodies (1:400 dilution, 2.5 μg/mL; Bio-
Vendor Laboratory Medicine, Inc., Evropska, Czech Re-
public), and were subsequently incubated for 20 min
with Envision (Dako Corporation, Copenhagen,
Denmark). The signal was detected by incubating the
sections with diaminobenzidine solution (Dako) and
hydrogen peroxide for one minute. We used image-J
software as an objective method to measure the intensity
of immunohistochemical staining for REG-I in biopsy
specimens of head and neck cancer.
Statistical analysis
It was performed using the IBM SPSS version 20 soft-
ware for Windows. Chi-square test and Fisher’s exact
test were used to check the association of categorical
variables. The Kaplan–Meier method was used to esti-
mate survival rate, and the log-rank test was used to
analyze survival differences. Overall survival time was
determined as the time from tumor diagnosis to death
from any cause. Disease free survival time was defined
as the time from treatment to tumor recurrence or
death.
Univariate and multivariate analyses were performed
using a Cox proportional hazards model to identify inde-
pendent prognostic factors. A statistically significant dif-
ference was considered with probability values of <0.05.
Results
REG-I expression was found to be either positive or
negative according to REG-I index
We found that REG-I staining of all specimens fell into
one of three groups; weak, moderate or strong staining,
which we scored as 1–3, respectively. We further mea-
sured the area of REG-I staining. Staining was scored as
0, 1, 2 or 3 if less than 10 %, 10 % or more but less than
50 %, 50 % or more but less than 90 %, or 90 % or more
of the tumor cells were stained, respectively. Finally, we
calculated a REG-I index (0–9) as the REG-I stained area
score (0–3) × REG-I intensity score (1–3) (Fig. 1). This
method was based on a previous report on esophageal
cancer [8].
After analysis of all specimens and calculation of the
REG-I index, we found that the patients could be grouped
into two main categories; those with a REG-I index ≥6,
which showed either strong staining with ≥50 % stained
area or moderate staining with >90 % stained area, where
most of specimens got REG-I index 6, and the remaining
specimens got REG-I index 9, and considered as REG-I
positive. The other category includes those with a REG-I
index 6, which showed either strong staining with <50 %
stained area, moderate staining with <90 % stained area, or
weak staining, where most of specimens got REG-I index 4
and the remaining specimens got REG-I index 3, 2 and 0,
Fig. 1 Immunohistochemical analysis of REG-I in biopsy specimens.
Representative immunohistochemical analysis of REG-I expression in
(a) a REG-I positive specimen with a REG-I index of 9, and (b) a REG-I
negative specimen with a REG-I index of 0 (Scale bar: 100 μm)
Table 3 Results of Fisher’s exact test and Chi-squared test in

















































































Aboshanif et al. Diagnostic Pathology  (2016) 11:79 Page 3 of 7and considered as REG-I negative (Table 2). After dividing
the specimens into two categories, we tried to test if there
is a difference between both groups in the clinico-
pathological parameters and survival rates.aChi-squared testAssociation of REG-I expression to the survival rates
We used Chi-square test and Fisher’s exact test to com-
pare the clinicopathological parameters between the
REG-I positive and negative groups (Table 3). This ana-
lysis indicated that the incidence of lymphatic perme-
ation, vascular invasion and pathological lymph nodes
was significantly higher in the REG-I negative groupTable 2 REG-I Index shows that all patients fall into two groups;
one group with index ≥6 and the other group with index <6
REG-I index Number of cases Total
9 2 36 positive cases
6 34
4 17 24 Negative cases
3 3
2 3
0 1than in the REG-I positive group (p = 0.008, 0.030 and
0.015, respectively) (Table 3).
Figure 2 shows Kaplan–Meier survival curves of
REG-I positive and negative groups. The overall sur-
vival rate was significantly higher in the REG-I posi-
tive group than in the REG-I negative group (5-year
survival rates were 86 and 52 %, respectively; p =
0.000434). Also, the cancer-free survival rate was sig-
nificantly higher among patients with a positive REG-
I index than among those with a negative index (5-
year survival rates were 59 and 8 %, respectively, p =
1.0847E-8).
Table 4 shows the results of univariate analysis. We
included 10 covariates: age, sex, lymphatic permeation
(yes / no), vascular invasion (yes / no), T-
classification (T1,2 / T3,4), N-classification (yes/no),
presence of postoperative positive lymph nodes (yes /
Fig. 2 Association of REG-I expression with patient survival rates. Overall
(a) and cancer free (b) survival rates of REG-I positive and REG-I negative
head and neck cancer patients analyzed using Kaplan Meier curves
Aboshanif et al. Diagnostic Pathology  (2016) 11:79 Page 4 of 7no), tumor grade (low, intermediate, high), site of
tumor (hypopharyngeal, oropharyngeal, tongue, larynx
and REG-I expression (positive / negative).
Univariate analysis showed that REG-I expression
(p = 0.002) was significant prognostic factor affecting
the overall survival with hazard ratio (95 % confi-
dence interval) of 0.144 (0.042– 0.497), while REG-I
expression (p = 0.000002), lymphatic permeation (p =
0.000088), vascular invasion (p = 0.004), and the pres-
ence of pathological lymph nodes (p = 0.003) weresignificant prognostic factors affecting the disease-free
survival.
Multivariate analysis using the Cox proportional haz-
ard model showed that REG-I expression (p = 0.001) and
lymphatic permeation (p = 0.022) are independent prog-
nostic factors for prediction of long-term disease-free
survival. The hazard ratio of REG-I expression (95 %
confidence interval) for the disease-free survival rate was
0.298 (0.141–0.626) (Table 5).
Discussion
There have been no previous reports of investigation of
the expression of REG-I in head and neck squamous cell
carcinoma. In the present study, 36 cases were positive
for REG-I expression, mainly with a REG-I index of 6.
We compared those patients with the REG-I negative
group (24 patients) and found that the REG-I positive
group had a lower incidence of lymphatic permeation
(absent in 22 patients (61 %) in the positive group but
only six patients (25 %) in the negative group) and vas-
cular invasion (absent in 27 patients (75 %) in the posi-
tive group and 11 patients (46 %) in the negative group);
and that pathological lymph nodes were absent in 26 pa-
tients (72 %) in the positive group, but only nine patients
(38 %) in the negative group. Also, it has been reported
that REG-Iα expression was significantly associated with
the prevalence of vascular invasion [9, 10].
But we could not find any significant difference be-
tween the two groups in terms of age, sex, clinical T-
stage, N-stage, or site of primary tumor. In lung SCC,
there was no significant difference in age, sex or tumor
stage between REG-Iα positive and negative groups [11].
Furthermore, as in case of esophageal squamous cell
carcinoma, we could not find any difference in regards
to grade of differentiation between the two groups [8]. It
has been reported that, REG-I was frequently expressed
by gastric carcinomas that were not well differentiated,
and identifying REG-I expression may help to detect ag-
gressive tumors [10].
Although, we could not prove that lymphatic perme-
ation, vascular invasion or pathological lymph nodes had
a significant effect on the overall survival, but we proved
that they could significantly affect the disease-free sur-
vival. On the other hand, it has been reported that vas-
cular invasion, lymph node metastasis and REG-Iα
expression were significantly predictive of overall sur-
vival in gastric tumors [9, 10]. Nevertheless, we found
that patients with a REG-I index of ≥6 had significantly
higher overall and disease free survival rates than pa-
tients with a REG-I index of <6.
To date, only two forms of the human REG-I gene,
REG-Iα and REG-Iβ, have been identified. The REG-Iα,
REG-Iβ and RS (REG-related sequence) genes are found
in a 95-kb region on chromosome 2p12 [12]. REG gene
Table 4 Univariate analysis of overall and disease-free survival rates
Survival rates
Variables
Overall survival Disease free survival
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tors that affect islet cells, neural cells and epithelial cells
of the digestive system [13, 14]. It also encodes proteins
involved not only in regeneration of damaged tissues,
but also in the growth of cancers [15–29].
We found that REG-I expression is associated with
longer survival in advanced head and neck cancer
treated by chemoradiotherapy; our results are consistent
with previous results regarding esophageal cancer [8].
On the other hand, Macadam et al. found that expres-
sion of REG mRNA was associated with a poor progno-
sis in surgically treated colon carcinoma patients, and
that the REG mRNA status was the only independent
factor for tumor recurrence [30]. It has also been dem-
onstrated that, REG-I positivity is associated with a
worse overall survival rate in patients with surgically
















0.001 0.141–0.626 (0.298)expression was an independent prognostic factor for
overall survival by multivariate analysis, but not for
disease-free survival [10]. This could be explained by the
differences between gastrointestinal cancers and esopha-
geal cancers; most esophageal cancers are SCCs, whereas
other gastrointestinal cancers are adenocarcinomas [11].
This conflicting findings regarding Reg-I positivity and
its effect on prognosis could be related to treatment
policy.
Finally, we have used a REG-I staining score developed
by one of our co-authors in a previous report for
esophageal cancer, but we have used image-J software as
an objective tool in measuring the area and strength of
the stain to avoid subjectivity. We also have used immu-
nohistochemistry, in spite of its known limitations to de-
termine the function of gene expression [31], to evaluate
REG-I expression and its correlation with the survival rate.
Further investigation of REG-I expression through evalu-
ation of REG messenger RNA is recommended [10].Conclusion
The results of our study indicate that REG-I is expressed
by advanced head and neck squamous cell carcinoma
and that REG-I positivity, in cases treated with chemo-
radiotherapy, is associated with a lower incidence of
lymphatic permeation, vascular invasion and patho-
logical lymph nodes. These findings may help in select-
ing the appropriate therapy for high-risk patients
(smokers, positive family history, etc.) with REG-I
Aboshanif et al. Diagnostic Pathology  (2016) 11:79 Page 6 of 7positive biopsy specimens. Furthermore, REG-I is a good
prognostic tool in late stage head and neck carcinoma.
Further studies are necessary to determine the role of
REG-Iα in head and neck cancer.
Abbreviations
HPV, human papilloma virus; REG, regenerating gene; SCCHN, squamous cell
carcinoma of the head and neck; SCCs, squamous cell carcinomas; WD, well
differentiated
Acknowledgements
We acknowledge the professional rewriting of the manuscript provided by
FORTE Science Communications Company.
Funding
Funding to perform this study, including the collection of materials and
immunohistochemistry, was received from the Japanese Society for promotion
of international Otorhinolaryngology (SPIO).
Availability of data and materials
All data were collected and recorded in Microsoft Excel. The clinical material
are immunostaining slides which are stored with the Microsoft Excel files in
the Otorhinolaryngology archives at our institution. All material is available
upon request through the corresponding author.
Authors’ contributions
KI, YO and SM conceived and designed the experiment. M A,YK,YO, SS and
KH carried out the experiments and participated in the data analysis and
drafted the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The study was approved by the ethics committee of Akita university
graduate school of medicine (reference number 1310). All participants had
signed a general consent at the time of surgical intervention for future use
of their materials for research purposes.
Author details
1Department of Otorhinolaryngology, Head and Neck Surgery, Akita
Graduate School of Medicine, Akita, Japan. 2Department of Molecular
Pathology and Tumor Pathology, Akita Graduate School of Medicine, Akita,
Japan. 3Department of Comprehensive Cancer Control, Akita Graduate
School of Medicine, Akita, Japan. 4Department of Otolaryngology Head and
Neck Surgery, Akita University, Graduate School of Medicine, 1-1-1, Hondo,
Akita 010-8543, Japan.
Received: 11 September 2015 Accepted: 4 August 2016
References
1. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of
head and neck cancer: a focus on human papillomavirus. J Dent Res.
2007;86:104–14.
2. Argiris A, Eng C. Epidemiology, staging, and screening of head and neck
cancer. Cancer Treat Res. 2003;114:15–60.
3. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case–
control study of human papillomavirus and oropharyngeal cancer. N Engl J
Med. 2007;356:1944–56.
4. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al.
SEER Cancer Statistics Review, 1975–2004. Bethesda: National Cancer
Institute; 2006.
5. Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino YO, et al.
A novel gene activated in regenerating islets. J Biol Chem. 1988;263:2111–4.
6. Nata K, Liu Y, Xu L, Ikeda T, Akiyama T, Noguchi N, et al. Molecular cloning,
expression and chromosomal localization of a novel human REG family
gene, REG III. Gene. 2004;340:161–70.7. Francis PJ, Southgate JL, Wilkin TJ, Bone AJ. Expression of an islet
regeneration (reg) gene in isolated rat islets: effects of nutrient and non-
nutrient growth factors. Diabetologia. 1992;35:238–42.
8. Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, et al.
REG I expression predicts long-term survival among locally advanced
thoracic squamous cell esophageal cancer patients treated with
neoadjuvant chemoradiotherapy followed by esophagectomy. Ann Surg
Oncol. 2006. doi:10.1245/s10434-006-9075-z.
9. Yamagishi H, Fukui H, Sekikawa A, Kono T, Fujii S, Ichikawa K, et al.
Expression profile of REG family proteins REG Iα and REG IV in advanced
gastric cancer: comparison with mucin phenotype and prognostic markers.
Mod Pathol. 2009;22:906–13.
10. Dhar DK, Udagawa J, Ishihara S, Otani H, Kinoshita Y, Takasawa S, et al.
Expression of regenerating gene I in gastric adenocarcinomas:
correlation with tumor differentiation status and patient survival.
Cancer. 2004;100:1130–6.
11. Kimura M, Naito H, Tojo T, Itaya-Hironaka A, Dohi Y, Yoshimura M, et al. REG
Iα gene expression is linked with the poor prognosis of lung
adenocarcinoma and squamous cell carcinoma patients via discrete
mechanisms. Oncol Rep. 2013;30:2625–31.
12. Zhang YW, Ding LS, Lai MD. Reg gene family and human diseases. World J
Gastroenterol. 2003;9:2635–41.
13. Dusetti NJ, Frigerio JM, Fox MF, Swallow DM, Dagorn JC, Iovanna JL.
Molecular cloning, genomic organization, and chromosomal localization
of the human pancreatitis-associated protein (PAP) gene. Genomics.
1994;19:108–14.
14. Broekaert D, Eyckerman S, Lavens D, Verhee A, Waelput W, Vandekerckhove J,
et al. Comparison of leptin- and interleukin-6-regulated expression of the rPAP
gene family: evidence for differential co-regulatory signals. Eur Cytokine Netw.
2002;13:78–85.
15. Sekikawa A, Fukui H, Fujii S, Nanakin A, Kanda N, Uenoyama Y, et al.
REG Iα protein may function as a trophic and/or anti-apoptotic factor
in the development of gastric cancer. Gastroenterology.
2005;128:642–53.
16. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, et al. Reg IV is a
serum biomarker for gastric cancer patients and predicts response to 5-
fluorouracil-based chemotherapy. Oncogene. 2007;26:4383–93.
17. Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S, et al. Serum
concentration of Reg IV in patients with colorectal cancer: over expression
and high serum levels of Reg IV are associated with liver metastasis.
Oncology. 2007;72:371–80.
18. Fukui H, Fujii S, Takeda J, Kayahara T, Sekikawa A, Nanakin A, et al.
Expression of REG Iα protein in human gastric cancers. Digestion. 2004;
69:177–84.
19. Sasaki Y, Minamiya Y, Takahashi N, Nakagawa T, Katayose Y, Ito A, et al.
REG1A expression is an independent factor predictive of poor prognosis in
patients with breast cancer. Ann Surg Oncol. 2008;15:3244–51.
20. Hayashi K, Motoyama S, Koyota S, Koizumi Y, Wang J, Takasawa S, et al. REG
I enhances chemo- and radiosensitivity in squamous cell esophageal cancer
cells. Cancer Sci. 2008;99:2491–5.
21. Hayashi K, Motoyama S, Sugiyama T, Izumi J, Anbai A, Nanjo H, et al. REG Iα
is a reliable marker of chemoradiosensitivity in squamous cell esophageal
cancer patients. Ann Surg Oncol. 2008;15:1224–31.
22. Usami S, Motoyama S, Koyota S, Wang J, Hayashi K, Maruyama K, et al.
Regenerating gene I regulates interleukin-6 production in squamous
esophageal cancer cells. Biochem Biophys Res Commun. 2010;392:4–8.
23. Kiji T, Dohi Y, Takasawa S, Okamoto H, Nonomura A, Taniguchi S. Activation
of regenerating gene Reg in rat and human hearts in response to acute
stress. Am J Physiol Heart Circ Physiol. 2005;289:H277–84.
24. Kiji T, Dohi Y, Nishizaki K, Takasawa S, Okamoto H, Nagasaka S, et al.
Enhancement of cell viability in cryopreserved rat vascular grafts by
administration of regenerating gene (REG) inducers. J Vasc Res. 2003;40:132–9.
25. Harada K, Zen Y, Kanemori Y, Chen C, Chen F, Yeh S, et al. Human REG I
gene is up-regulated in intrahepatic cholangiocarcinoma and its precursor
lesions. Hepatology. 2001;33:1036–42.
26. Ohara S, Oue N, Matsubara A, Mita K, Hasegawa Y, Hayashi T, et al. Reg IV is
an independent prognostic factor for relapse in patients with clinically
localized prostate cancer. Cancer Sci. 2008;99:1570–7.
27. Zhou L, Zhang R, Wang L, Shen S, Okamoto H, Sugawara A, et al.
Upregulation of REG Iα accelerates tumor progression in pancreatic cancer
with diabetes. Int J Cancer. 2010;127:1795–803.
Aboshanif et al. Diagnostic Pathology  (2016) 11:79 Page 7 of 728. Yonemura Y, Sakurai S, Yamamoto H, Endou Y, Kawamura T, Bandou E, et al.
REG gene expression is associated with the infiltrating growth of gastric
carcinoma. Cancer. 2003;98:1394–400.
29. Zheng HC, Sugawara A, Okamoto H, Takasawa S, Takahashi H, Masuda S,
et al. Expression profile of the REG gene family in colorectal carcinoma. J
Histochem Cytochem. 2011;59:106–15.
30. Macadam RCA, Sarela AI, Farmey SM, Robinson PA, Markham AF, Guillou PJ.
Death from early colorectal cancer is predicted by the presence of
transcripts of the REG gene family. Br J Cancer. 2000;83:188–95.
31. Matos LL, Trufelli DC, de Matos MG, da Silva PMA. Immunohistochemistry as
an important tool in biomarkers detection and clinical practice. Biomark
Insights. 2010;5:9–20.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
